# US 2021/0145771 A1 · N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0145771 A1
- Document ID: US20210145771A1
- Status: Published application
- Kind: A1
- Application number: 16/623,553
- Filed: 2018-07-02
- Published: 2021-05-20
- Earliest claimed: 2017-07-03
- Assignees: GlaxoSmithKline Intellectual Property Development Limited
- Applicants: GlaxoSmithKline Intellectual Property Development Limited
- Inventors: Mui CHEUNG; Michael P. DEMARTINO; Biswajit KALITA
- Web page: https://patentgrep.com/patent/US20210145771A1

## CPC

- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61P 35/00: Antineoplastic agents
- A61K 31/164: of a carboxylic acid with an aminoalcohol, e.g. ceramides
- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/351: not condensed with another ring
- A61K 31/401: Proline; Derivatives thereof, e.g. captopril
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07C 233/74: with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
- C07C 235/14: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C 235/22: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C 237/04: the carbon skeleton being acyclic and saturated
- C07C 237/06: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 237/08: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C 237/14: the carbon skeleton being saturated and containing rings
- C07C 271/24: with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 211/38: Halogen atoms or nitro radicals
- C07D 211/40: Oxygen atoms
- C07D 211/76: attached in position 2 or 6
- C07D 307/24: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 309/08: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07C 2601/02: with a three-membered ring
- C07C 2601/04: with a four-membered ring
- C07C 2601/08: the ring being saturated
- C07C 2601/14: The ring being saturated
- C07C 2602/38: the bicyclo ring system containing five carbon atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein X, a, b, C, D, L2, L3, Y1, Y2, R2, R4, R5, R6, z2, z4, z5, and z6 are as defined herein, and salts thereof. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

## Claims

### Claim 1

A compound according to Formula (I):
wherein:
L2 is a bond or selected from: —NR9—, —O—, —S—, —S(O)—, —S(O)2—, C1-8alkylene, substituted C1-8alkylene, C1-8alkyl, substituted C1-8alkyl, C1-8heteroalkylene, substituted C1-8heteroalkylene, C1-8heteroalkyl, and substituted C1-8heteroalkyl;
L3 is absent, a bond or selected from: —NR2—, —O—, —S—, —S(O)—, —S(O)2—, C1-8alkylene, substituted C1-8alkylene, C1-8alkyl, substituted C1-8alkyl, C1-8heteroalkyl, substituted C1-8heteroalkyl, C1-8heteroalkylene and substituted C1-8heteroalkylene;
Y1 is selected from: NH—, NH2, a nitrogen linked heterocycloalkyl, and a substituted nitrogen linked heterocycloalkyl;
Y2 is absent, a bond or selected from: C1-2alkylene and C1-2alkylene substituted from 1 to 4 times by fluoro;
R5 and R6, when present, are independently selected from: fluoro, chloro, bromo, iodo, oxo, —OCH3, —OCH2Ph, —C(O)Ph, —CH3, —CF3, —CHF2, —CH2F, —CN, —S(O)CH3, —S(O)2CH3, —OH, —NH2, —NHCH3, —N(CH3)2, —COOH, —CONH2, —NO2, —C(O)CH3, —CH(CH3)2, —C(CF3)3, —C(CH3)3, —CH2—CF3, —CH2—CH3, —CCH, —CH2CCH, —SO3H, —SO2NH2, —NHC(O)NH2, —NHC(O)H, —NHOH, —OCF3, —OCHF2, C1-6alkyl, substituted C1-6alkyl, heteroalkyl, substituted heteroalkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
R2 and R4, when present, are independently selected from: NR8, O, CH2, and S;
R8 is selected from: hydrogen, —OH, C1-6alkyl and C1-6alkyl substituted 1 to 6 times by fluoro;
R9 is selected from: hydrogen, C1-6alkyl and C1-6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
C is absent or selected from: phenyl, pyridyl, and cycloalkyl;
D is absent or selected from: cycloalkyl, and substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl;
X is C1-3alkyl or C1-3alkyl substituted 1 to 3 times by fluoro;
z2 and z4 are independently 0 or 1; and
z5 and z6 are independently an integer from 0 to 5;
provided:
when Y1 is NH2, heterocycloalkyl, or substituted heterocycloalkyl; Y2, L3, and D are absent and z6 is 0;
when L2 is monovalent; C is absent and z5 is 0; and
when L3 is monovalent; D is absent and z6 is 0;
or a salt thereof including a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 represented by the following Formula (II):
wherein:
L12 is a bond or selected from: —CH2—O—, and —CH2—CH2—O—;
L13 is a bond or selected from: —CH2—, —CH2—O—CH3, —CH2—O—, —CH2—O—CH2—CH3, —CH2—O—CH2—CH2—CH2—CH3, —CH2—O—CH2—, —CH2—O—CH2—CH2—CH3, —CH2—CH2—CH3, —CH2—O—CH2—CH(CH3)2, —CH2—O—CH(CH3)2, —CH2—O—C(CH3)3, —CH2—O—CH2—CF3, —CH2—O—C(CH3)2—CF3, —CH2—C(CH3)3, —CH2—O—CH2—(CH3)3, —CH2—O—C(CH3)H—CF3, —CH2—CH2—C(CH3)3, —CH2—CF3, —CH2—O—C(CH3)H—, —CH2—O—C(CH3)H—CH2—CH3, —CH3, —CH2—CH3, —CH2—O—C(CH3)H—CH2—CH2—CH3, —CH2—O—CH2—CH2—O—CH3, —CH2—O—C(CH3)H—CH(CH3)2, —CH2—O—C(CH3)H—CH2—, —CH2—O—C(CH3)2—, —CH2—O—C(CH3)H—CH2O—CH3, —C(CH3)HO—CH3, —CH2—CH2—, —CH2—CH2—O—C(CH3)H—, —CH2—CH2—O—, —CH2—N(CH3)2, —CH2—NH(CH3), —CH2—N(CH3)—CH(CH3)—, —CH2—N(CH3)—CH2—CH2—CH3, —CH2—NH—CH2—CH2—CH3, —N(CH3)2, —CH2—NH—CH2—CH2—O—CH3, —CH2—NH—CH2—CH3, —NH(CH3), —CH2—N(CH3)—CH2—CH3, —CH2—N(CH3)—CH(CH3)2, —CH(CF3)—N(CH3)2, —CH(N(CH3)2)—CH(CH3)2, —CH(CH3)—N(CH3)2, and —C(CH3)2—N(CH3)2;
Y11 is selected from: NH—, NH2, a nitrogen linked heterocycloalkyl, and a nitrogen linked heterocycloalkyl substituted from 1 to 3 times by a substituent selected from: fluoro, chloro, bromo, iodo, oxo, —OCH3, —OCF3, —CH3, and —CF3;
Y12 is absent, a bond or selected from: —CH2—, and —CH2—, substituted once or twice by fluoro;
R15, when present, is selected from chloro, —C(CF3)3, and —C(CH3)3;
R16, when present, is selected from: fluoro, chloro, bromo, —C(CF3)3, —C(CH3)3, —CH2—CF3, —CH2—CH3, —CH3, —CF3, and —N(CH3)2;
C1 is absent or selected from: phenyl, and cyclopropyl;
D1 is absent or selected from: piperidinyl, cyclohexyl, cyclopropyl, cyclopentyl, cyclobutyl, pyrrolidinyl, tetrahydrofuranyl, and tetrahydropyranyl;
z12 and z14 are independently 0 or 1; and
z15 and z16 are independently an integer from 0 to 4;
provided:
when Y11 is NH2, heterocycloalkyl, or substituted heterocycloalkyl; Y12, L13, and D1 are absent and z16 is 0; and
when L13 is monovalent; D1 is absent;
or a salt thereof including a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

A compound of claim 1 represented by the following Formula (III):
wherein:
L22 is a bond or selected from: —CH2—O—, and —CH2—CH2—O—;
L23 is a bond or selected from: —CH2—, —CH2—O—CH3, —CH2—O—, —CH2—O—CH2—CH3, —CH2—O—CH2—CH2—CH2—CH3, —CH2—O—CH2—, —CH2—O—CH2—CH2—CH3, —CH2—CH2—CH3, —CH2—O—CH2—CH(CH3)2, —CH2—O—CH(CH3)2, —CH2—O—C(CH3)3, —CH2—O—CH2—CF3, —CH2—O—C(CH3)2—CF3, —CH2—C(CH3)3, —CH2—O—CH2—(CH3)3, —CH2—O—C(CH3)H—CF3, —CH2—CH2—C(CH3)3, —CH2—CF3, —CH2—O—C(CH3)H—, —CH2—O—C(CH3)H—CH2—CH3, —CH3, —CH2—CH3, —CH2—O—C(CH3)H—CH2—CH2—CH3, —CH2—O—CH2—CH2—O—CH3, —CH2—O—C(CH3)H—CH(CH3)2, —CH2—O—C(CH3)H—CH2—, —CH2—O—C(CH3)2—, —CH2—O—C(CH3)H—CH2—O—CH3, —C(CH3)HO—CH3, —CH2—CH2—, —CH2—CH2—O—C(CH3)H—, —CH2—CH2—O—, —CH2—N(CH3)2, —CH2—NH(CH3), —CH2—N(CH3)—CH(CH3)—, —CH2—N(CH3)—CH2—CH2—CH3, —CH2—NH—CH2—CH2—CH3, —N(CH3)2, —CH2—NH—CH2—CH2—O—CH3, —CH2—NH—CH2—CH3, —NH(CH3), —CH2—N(CH3)—CH2—CH3, —CH2—N(CH3)—CH(CH3)2, —CH(CF3)—N(CH3)2, —CH(N(CH3)2)—CH(CH3)2, —CH(CH3)—N(CH3)2, and —C(CH3)2—N(CH3)2;
R25, when present, is selected from chloro, —C(CF3)3, and —C(CH3)3;
R26, when present, is selected from: fluoro, chloro, bromo, —C(CF3)3, —C(CH3)3, —CH2—CF3, —CH2—CH3, —CH3, —CF3, and —N(CH3)2;
D2 is absent or selected from: piperidinyl, cyclohexyl, cyclopropyl, cyclopentyl, cyclobutyl, pyrrolidinyl, tetrahydrofuranyl, and tetrahydropyranyl; and
z25 and z26 are independently an integer from 0 to 4;
provided:
when L23 is monovalent, D2 is absent and z26 is 0; and
when D2 is absent L23 is not a bond;
or a salt thereof including a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

A compound of claim 1 represented by the following Formula (IV):
wherein:
L33 is a bond or selected from: —CH2—, —CH2—O—CH3, —CH2—O—, —CH2—O—CH2—CH3, —CH2—O—CH2—CH2—CH2—CH3, —CH2—O—CH2—, —CH2—O—CH2—CH2—CH3, —CH2—CH2—CH3, —CH2—O—CH2—CH(CH3)2, —CH2—O—CH(CH3)2, —CH2—O—C(CH3)3, —CH2—O—CH2—CF3, —CH2—O—C(CH3)2—CF3, —CH2—C(CH3)3, —CH2—O—CH2—(CH3)3, —CH2—O—C(CH3)H—CF3, —CH2—CH2—C(CH3)3, —CH2—CF3, —CH2—O—C(CH3)H—, —CH2—O—C(CH3)H—CH2—CH3, —CH3, —CH2—CH3, —CH2—O—C(CH3)H—CH2—CH2—CH3, —CH2—O—CH2—CH2—O—CH3, —CH2—O—C(CH3)H—CH(CH3)2, —CH2—O—C(CH3)H—CH2—, —CH2—O—C(CH3)2—, —CH2—O—C(CH3)H—CH2—O—CH3, —C(CH3)HO—CH3, —CH2—CH2—, —CH2—CH2—O—C(CH3)H—, —CH2—CH2—O—, —CH2—N(CH3)2, —CH2—NH(CH3), —CH2—N(CH3)—CH(CH3)—, —CH2—N(CH3)—CH2—CH2—CH3, —CH2—NH—CH2—CH2—CH3, —N(CH3)2, —CH2—NH—CH2—CH2—O—CH3, —CH2—NH—CH2—CH3, —NH(CH3), —CH2—N(CH3)—CH2—CH3, —CH2—N(CH3)—CH(CH3)2, —CH(CF3)—N(CH3)2, —CH(N(CH3)2)—CH(CH3)2, —CH(CH3)—N(CH3)2, and —C(CH3)2—N(CH3)2;
R36, when present, is selected from: fluoro, chloro, bromo, —C(CF3)3, —C(CH3)3, —CH2—CF3, —CH2—CH3, —CH3, —CF3, and —N(CH3)2;
D3 is absent or selected from: piperidinyl, cyclohexyl, cyclopropyl, cyclopentyl, cyclobutyl, pyrrolidinyl, tetrahydrofuranyl, and tetrahydropyranyl; and
z36 is an integer from 0 to 2;
provided:
when L33 is monovalent, D3 is absent and z36 is 0; and
when D3 is absent L33 is not a bond;
or a salt thereof including a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1 selected from:
2-(4-chlorophenoxy)-N-(3-(2-(cyclohexyloxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(2,2,2-trifluoroethoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(1-methylcyclobutoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(pentan-2-yloxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-((1,1,1-trifluoro-2-methylpropan-2-yl)oxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-((1-methylcyclopropyl)methoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-((1-cyclopropylpropan-2-yl)oxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(cyclopropylmethoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(tert-butoxy)-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-isobutoxyacetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(1-methylcyclopropoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(neopentyloxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(cyclopentyloxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(sec-butoxy)-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-cyclopropoxyacetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(1-cyclopropylethoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(2-methoxyethoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(1,2-dimethylcyclopropoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-((1-methoxypropan-2-yl)oxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(1-methylcyclopropoxy)-N-(3-(2-(p-tolyloxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-((1,1,1-trifluoropropan-2-yl)oxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-butoxy-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-isopropoxyacetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-ethoxyacetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-((3-methylbutan-2-yl)oxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-propoxyacetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-methoxyacetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(4,4-difluoropiperidin-1-yl)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-((2-(1-methylcyclopropoxy)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-((2-(1-cyclopropylethoxy)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-methylcyclopropane-1-carboxamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)tetrahydrofuranyl-2-carboxamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)tetrahydro-2H-pyran-2-carboxamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)cyclobutanecarboxamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-1-(trifluoromethyl)cyclopropane-1-carboxamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)cyclopropanecarboxamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-1-methylcyclopropane-1-carboxamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-4,4-dimethylpentanamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)propionamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-3,3,3-trifluoropropanamide;
2-(4-chlorophenoxy)-N-(3-(2-cyclopropylacetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2,2-dimethylcyclopropane-1-carboxamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)butyramide;
N-(3-acetamidobicyclo[1.1.1]pentan-1-yl)-2-(4-chlorophenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(dimethylamino)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
(R)—N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-(dimethylamino)-3-methylbutanamide;
(S)—N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-(dimethylamino)-3-methylbutanamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-3,3-dimethylbutanamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2,2-difluorocyclopropane-1-carboxamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-methoxypropanamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-(dimethylamino)-2-methylpropanamide;
2-(4-chlorophenoxy)-N-(3-(2-(methylamino)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide hydrochloride;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)pyrrolidinyl-2-carboxamide hydrochloride;
(S)—N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-(dimethylamino)propanamide;
(R)—N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-(dimethylamino)propanamide;
2-(4-chlorophenoxy)-N-(3-(2-(propylamino)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(ethylamino)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(isopropyl(methyl)amino)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-((2-(methylamino)-2-oxoethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-((3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)amino)-N,N-dimethylacetamide;
(R)-2-(4-chlorophenoxy)-N-(3-(2-((1-cyclopropylethyl)(methyl)amino)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-((2-methoxyethyl)-l3-chloranyl)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-1-(dimethylamino)cyclopropanecarboxamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-(dimethylamino)-3,3,3-trifluoropropanamide;
2-(4-chlorophenoxy)-N-(3-(2-(methyl(propyl)amino)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(ethyl(methyl)amino)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
N,N′-(bicyclo[1.1.1]pentane-1,3-diyl)bis(2-(terf-butoxy)acetamide);
N,N′-(bicyclo[1.1.1]pentane-1,3-diyl)bis(2-(1-methylcyclopropoxy)acetamide);
(1-methylcyclopropyl)methyl (3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate;
N-(3-aminobicyclo[1.1.1]pentan-1-yl)-2-(4-chlorophenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-oxopiperidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide; and
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-1-fluorocyclopropane-1-carboxamide;
or a salt thereof including a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

### Claim 7 (depends on 1)

A method of treating a disease selected from: cancer, pre-cancerous syndromes, Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, traumatic brain injury, cognitive impairment, atherosclerosis, ocular diseases, in organ transplantation and arrhythmias, in a human in need thereof, which comprises administering to such human a therapeutically effective amount of a compound as described in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim at position 8

8-13. (canceled)

### Claim 14 (depends on 1)

The method of inhibiting the ATF4 pathway in a human in need thereof, which comprises administering to such human a therapeutically effective amount of a compound as described in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

A method of treating cancer in a human in need thereof, which comprises: administering to such human a therapeutically effective amount of
a) a compound as described in claim 1 or a pharmaceutically acceptable salt thereof; and
b) at least one anti-neoplastic agent.

### Claim at position 12

17-19. (canceled)

### Claim 20 (depends on 7)

The method according to claim 7 wherein said cancer is selected from: breast cancer, inflammatory breast cancer, ductal carcinoma, lobular carcinoma, colon cancer, pancreatic cancer, insulinomas, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, glucagonoma, skin cancer, melanoma, metastatic melanoma, lung cancer, small cell lung cancer, non-small cell lung cancer, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, brain (gliomas), glioblastomas, astrocytomas, glioblastoma multiforme, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma, medulloblastoma, head and neck, kidney, liver, melanoma, ovarian, pancreatic, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, glucagonoma, insulinoma, prostate, sarcoma, osteosarcoma, giant cell tumor of bone, thyroid,
lymphoblastic T cell leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, hairy-cell leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic neutrophilic leukemia, acute lymphoblastic T cell leukemia, plasmacytoma, Immunoblastic large cell leukemia, mantle cell leukemia, multiple myeloma, megakaryoblastic leukemia, multiple myeloma, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia,
malignant lymphoma, hodgkins lymphoma, non-hodgkins lymphoma, lymphoblastic T cell lymphoma, Burkitt's lymphoma, follicular lymphoma,
neuroblastoma, bladder cancer, urothelial cancer, vulval cancer, cervical cancer, endometrial cancer, renal cancer, mesothelioma, esophageal cancer, salivary gland cancer, hepatocellular cancer, gastric cancer, nasopharangeal cancer, buccal cancer, cancer of the mouth, GIST (gastrointestinal stromal tumor), neuroendocrine cancers and testicular cancer.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable excipient and an effective amount of a compound as described in claim 1 or a pharmaceutically acceptable salt thereof, which process comprises bringing the compound or a pharmaceutically acceptable salt thereof into association with a pharmaceutically acceptable excipient.

### Claim 23 (depends on 7)

The method according to claim 7 wherein said pre-cancerous syndrome is selected from: cervical intraepithelial neoplasia, monoclonal gammapathy of unknown significance (MGUS), myelodysplastic syndrome, aplastic anemia, cervical lesions, skin nevi (pre-melanoma), prostatic intraepithelial (intraductal) neoplasia (PIN), Ductal Carcinoma in situ (DCIS), colon polyps and severe hepatitis or cirrhosis.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

A method of treating ocular diseases in a human in need thereof, which comprises administering to such human a therapeutically effective amount of a compound as described in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 25)

A method according to claim 25 wherein the ocular disease is selected from: rubeosis irides; neovascular glaucoma; pterygium; vascularized glaucoma filtering blebs; conjunctival papilloma; choroidal neovascularization associated with age-related macular degeneration (AMD), myopia, prior uveitis, trauma, or idiopathic; macular edema; retinal neovascularization due to diabetes; age-related macular degeneration (AMD); macular degeneration; ocular ischemic syndrome from carotid artery disease; ophthalmic or retinal artery occlusion; sickle cell retinopathy; retinopathy of prematurity; Eale's Disease; and VonHippel-Lindau syndrome.

### Claim 27 (depends on 25)

A method according to claim 25 wherein the ocular disease is selected form: age-related macular degeneration (AMD) and macular degeneration.

### Claim 28 (depends on 1)

A method of treating neurodegeneration in a human in need thereof, which comprises administering to such human a therapeutically effective amount of a compound of Formula (I), as described in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 29 (depends on 1)

A method of preventing organ damage during the transportation of organs for transplantation, which comprises adding a compound as described in claim 1 or a pharmaceutically acceptable salt thereof, to a solution housing the organ during transportation.

### Claim at position 23

30-37. (canceled)

### Claim 38 (depends on 1)

A method of treating a disease associated with phosphorylation of eIF2α in a human in need thereof, which comprises administering to such human a therapeutically effective amount of a compound of Formula (I), as described in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 39 (depends on 1)

A method of treating an integrated stress response associated disease in a human in need thereof, which comprises administering to such human a therapeutically effective amount of a compound of Formula (I), as described in claim 1 or a pharmaceutically acceptable salt thereof.
